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We describe a 34-year old man presenting with subacute generalized myasthenic symptoms. His clinical features and laboratory
investigations demonstrated both myasthenia gravis and myotonic dystrophy type 1. The computerized tomography of chest revealed
anterior mediastinal mass. The lymphocyte-rich thymoma was removed surgically and he received radiotherapy. Recent observations
suggested that the patients with myotonic dystrophy may have an increased risk of benign and malignant tumours but its coexistence
with thymoma is very rare. The risk of thymoma associated with myotonic dystrophy is unknown.
 2013 The Authors. Published by Elsevier B.V.
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Myotonic dystrophy is an inherited disease
characterized by weakness, myotonia and early onset
cataracts. It is a slowly progressive multisystemic disorder
that aﬀects the heart, eyes and, gastrointestinal, endocrine
and central nervous systems [1]. Myotonic dystrophy is
the most common form of muscular dystrophy in adults
with prevalence of 1 case per 8000 people [2].
Molecular genetic studies have identiﬁed two types of
myotonic dystrophy. Type 1 (DM1) is caused by a CTG
repeat expansion in the untranslated region of the
dystrophia myotonica protein kinase (DMPK) gene on
chromosome 19q13.3, and type 2 (DM2) results from a
CCTG repeat expansion in intron 1 of the zinc ﬁnger 90960-8966  2013 The Authors. Published by Elsevier B.V.
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Open access undegene on chromosome 3q21. The proportions of myotonic
dystrophy patients with DM1 and DM2 are unknown [1].
Recent studies have suggested that myotonic dystrophy
is associated with an increased risk of benign and
malignant tumours [2–5]. The association of myotonic
dystrophy with thymoma and myasthenia gravis is very
rare [2,3,6]. In this report, we present a patient with
myotonic dystophy coexisting with myasthenia gravis and
thymoma.2. Case
A 34-year-old man was admitted to the hospital with a
2 weeks history of fatigue, dysphagia, eyelid fall and
weakness. His initial complaints were fatigue and ptosis
of the left eyelid. Diﬃculty swallowing and, weakness
that ﬂuctuated throughout the day in his arms, legs and
neck muscles occurred within 2 weeks. His medical
history, revealed infertility with oligospermia. His older
brother had been surgically treated for early onset
cataract and was also infertile with oligospermia.
A neurological examination, demonstrated mild ptosis
in his left eyelid and bilateral facial weakness, but nor CC BY-NC-SA license.
Fig. 1. Ptosis and facial weakness.
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generalized weakness in his arms, legs and neck muscles.
He had nasal speech and complained of diﬃculty
swallowing and chewing. The Simpson test was positive.
These ﬁndings suggested a diagnosis of myasthenia
gravis, but we also observed handgrip myotonia during a
thorough examination in the neuromuscular clinic. He
had percussion myotonia of the thenar and tongue
muscles. (Fig. 2) He had been unaware of his myotonic
symptoms.
His complete blood count, erythrocyte sedimentation
rate, serum chemistries and thyroid hormone levels were
normal. Anti-thyroperoxidase and anti-thyroglobulin
antibodies were negative. The acetylcholine receptor
(AChR) antibody titre was 14 nmol/L (normal
<0.5 nmol/L). Needle electromyography demonstrated
myotonic discharges, short-duration motor unit action
potentials and early recruitment. There was a
20% decremental response to 3–5 Hz repetitive
stimulation. A computerized tomography scan of his
chest showed a 2.3  1.8 cm anterior mediastinal mass.
Echocardiography showed diastolic dysfunction of the
left ventricle.Fig. 2. Myotonia with percussion of the tongue.His brother was invited to undergo a neurological
examination; he had bilateral weakness of the facial and
neck ﬂexor muscles and, eyelids and grip myotonia.
Percussion myotonia of the thenar and tongue muscles
was also noted. He was also unaware of his myotonic
symptoms. Needle EMG revealed myotonic discharges,
short duration motor unit action potentials, early
recruitment. Repetitive nerve stimulation test at 3–5 Hz
was normal.
The clinical features, acetylcholine receptor antibody
positivity and decremental response to repetitive
stimulation conﬁrmed the diagnosis of myasthenia gravis.
However the presence of clinical, electrophysiological
myotonia and positive family history supported a
diagnosis of myotonic dystrophy. A molecular genetic
analysis revealed an expansion due to 80 CTG repeats in
the untranslated region of DMPK gene. He was
diagnosed with both myasthenia gravis and myotonic
dystrophy type 1 based on his clinical and laboratory
features.
The patient was started on pyridostigmine at a dosage
60 mg three times daily and administered intravenous
immunoglobulin (IVIG) (total dose 2 gr/kg for 3 days)
for his bulbar symptoms. After IVIG therapy, his
dysphagia, ptosis, and extremity and neck weakness
improved, but his nasal speech and facial weakness
continued. Oral prednisolone (60 mg/day) was added to
the treatment regimen and he underwent surgery for the
anterior mediastinal mass. The mass was found to be a
type 1B thymoma (lymphocyte-rich thymoma) and the
mediastinal fat tissue was inﬁltrated. He subsequently
received radiotherapy.
At a 10-months follow up, his myasthenic symptoms
were improved. However, his myotonic symptoms and
facial weakness remained the same without troubling
him. Electrodiagnostic tests and AChR antibody titre
were repeated after 10 months. Needle EMG study
demonstrated myotonic discharges and short duration
motor unit potetntials and early recruitment. There was
no decremental response to 3–5 Hz stimulation. AChR
antibody titre did not decrease (15 nmol/L).
3. Discussion
Myotonic dystrophy is very rarely associated with both
thymoma and myasthenia gravis, and only nine cases with
myotonic dystrophy and thymoma have been reported
since 1969 [2,6–12]. Only two cases had both thymoma
and myasthenia gravis. Additionally, three cases with
myotonic dystrophy and myasthenia gravis have been
reported [13–15].
Recent studies have suggested that patients with
myotonic dystrophy have an increased risk of benign and
malignant tumours [2–5]. Pilomatricoma is the most
commonly reported tumour and several reports have
suggested that multiple basal cell carcinomas may be a
phenotypic variant of myotonic dystrophy [2]. Gadalla et
42 O. Ekmekci et al. / Neuromuscular Disorders 24 (2014) 40–42al. reported an increased risk for malignancy of the
endometrium, brain, ovary and colon [3]. Win et al. also
demonstrated an increased risk of thyroid cancer and
choroidal melanoma compared with the general
population. However their study also indicated an
increased risk for cancers of the prostate and testicles [4].
In Das’ study, myotonic dystrophy type 1 and female
gender were associated with tumour development. They
suggested that patients who were female or had myotonic
dystrophy type 1 were more likely to develop tumours
than male or individuals with type 2 [5].
Several mechanisms for the increased cancer risk have
been postulated, including; RNA-mediated alterations in
tumour suppressor genes, oncogene expression and
modiﬁcation of the coding features of proteins [3]. The
CTG expansions in DMPK and the CCTG expansions in
ZNF9 do not alter the protein coding-portion of their
respective genes, but their mutant mRNA are sequestered
in the nucleus and alter the function of RNA splicing
factors such as muscleblind (MBNL1), and the
CUG-BP1 and ETR-3-like factors (CELF) family of
RNA binding proteins [1]. Mueller et al. hypothesized
that tumour progression in myotonic dystrophy also
involves the up regulation of beta catenin via the Wnt
signaling pathway, possibly via the actions of RNA
splicing factors (CUG-BP or MBNL). In human
ﬁbroblasts, CUG-BP1 has been shown to block
calcireticulin mediated repression of p21 translation.
Increased expression of p21 is a somatic molecular
characteristic of thymomas. p21 plays a major role in
oncogenesis and has also been implicated in apoptosis,
terminal diﬀerentiation and replicate senescence via
interaction with such well known tumour suppressor
genes as p53 and BRCA, as well as genes in the Wnt/
beta catenin signaling pathway [1]. DMPK is a member
of a large gene family that contains cancer susceptibility
genes such as RET (multiple endocrine neoplasia type 2),
STK11 (Peutz-Jeghers syndrome) and, ALK
(neuroblastoma) [5]. DMPK may also be a cancer
susceptibility gene.
In this case, there is an association between myotonic
dystrophy and thymoma. Myasthenic symptoms are due
to paraneoplastic myasthenia gravis.
The risk of thymoma in patients with myotonic
dystrophy is unknown. The concurrent presence of
thymoma and myotonic dystrophy has been reported inonly a few case reports. If the symptoms of myotonic
dystrophy in a patient coexist with thymoma and
myasthenia gravis are subtle or mild, the diagnosis may
be missed. It is important to be aware of these
associations because early diagnosis with proper
treatment will provide a better outcome.
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